Advertisement
Screener

ATARA BIOTHERAPEUTICS, INC. (ATRA) Increase (Decrease) in Restricted Cash

2.8 / 5 stars · 68/120 Roast Me

ATARA BIOTHERAPEUTICS, INC. Increase (Decrease) in Restricted Cash

ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Increase (Decrease) in Restricted Cash of $1.20 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-27.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2018-02-27

  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in restricted cash for the quarter ending 2017-12-31 was $0.00.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in restricted cash for the quarter ending 2017-09-30 was $0.00.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in restricted cash for the quarter ending 2017-06-30 was $0.00.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in restricted cash for the quarter ending 2017-03-31 was $1.20M.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in restricted cash for fiscal 2017 was $1.20M.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in restricted cash for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
  • ATARA BIOTHERAPEUTICS, INC. increase (decrease) in restricted cash for fiscal 2015 was $194.00K.
Period endIncrease (Decrease) in Restricted Cash 3 monthIncrease (Decrease) in Restricted Cash 6 monthIncrease (Decrease) in Restricted Cash 9 monthIncrease (Decrease) in Restricted Cash 12 month
2017-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$0.00
derived: sum of 2 quarters · filed 2018-02-27
$0.00
derived: sum of 3 quarters · filed 2018-02-27
$1.20M
10-K · filed 2018-02-27
2017-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
$0.00
derived: sum of 2 quarters · filed 2017-11-09
$1.20M
10-Q · filed 2017-11-09
$1.20M
derived: sum of 4 quarters · filed 2018-02-27
2017-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07
$1.20M
10-Q · filed 2017-08-07
$1.20M
derived: sum of 3 quarters · filed 2018-02-27
$1.20M
derived: sum of 4 quarters · filed 2018-02-27
2017-03-31$1.20M
10-Q · filed 2017-05-04
$1.20M
derived: sum of 2 quarters · filed 2018-02-27
$1.20M
derived: sum of 3 quarters · filed 2018-02-27
$1.20M
derived: sum of 4 quarters · filed 2018-02-27
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$0.00
derived: sum of 2 quarters · filed 2018-02-27
$0.00
derived: sum of 3 quarters · filed 2018-02-27
$0.00
10-K · filed 2018-02-27
2016-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
$0.00
derived: sum of 2 quarters · filed 2017-11-09
$0.00
10-Q · filed 2017-11-09
2016-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07
$0.00
10-Q · filed 2017-08-07
2016-03-31$0.00
10-Q · filed 2017-05-04
2015-12-31$194.00K
10-K · filed 2018-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
Vaxart, Inc. (VXRT)United States$0.080B3.84
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02
BioStem Technologies, Inc. (BSEM)United States$0.069B
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37